Last Update 01 Apr 26
Fair value Increased 0.35%SBRA: Senior Housing Occupancy Recovery Will Drive Confidence In 2026 FFO Outlook
Sabra Health Care REIT's analyst price target has edged higher to about $21.92 from $21.85, as analysts point to stronger potential revenue growth and improved senior housing occupancy prospects, partly offset by slightly softer profit margin expectations.
Analyst Commentary
Recent Street research on Sabra Health Care REIT has centered on refreshed valuation work following Q4 results, with several firms adjusting price targets and revisiting their views on occupancy trends, capital deployment, and funds from operations guidance.
Bullish Takeaways
- Bullish analysts point to what they see as good upside potential in the senior housing portfolio occupancy, which they view as an important driver for Sabra's revenue trajectory and ability to support its valuation.
- Some research notes highlight an improved investment yield spread over Sabra's cost of capital at recent share prices, which these analysts see as supportive of the REIT's ability to pursue accretive investments.
- Price target increases clustered in the low US$20s, with a few as high as US$23 to US$24, indicate that several analysts see room for execution on growth initiatives and capital allocation, even while keeping neutral or hold ratings in place.
- Following the Q4 report, certain bullish analysts updated their estimates and raised targets after reassessing Sabra's portfolio mix and its potential to support steady funds from operations over their modeling horizon.
Bearish Takeaways
- Bearish analysts, or those keeping neutral or hold ratings, still flag caution around profit margin expectations, which they see as slightly softer and a constraint on how far valuation can move relative to their targets.
- One research note points out that Sabra's 2026 FFO guidance came in just below prior consensus, suggesting execution risk around hitting those targets even if the shortfall is described as recoverable.
- Some cautious commentary stresses the need for higher target development yields across REITs to prioritize near term FFO per share impact, which may limit how aggressively Sabra can pursue new projects without careful return discipline.
- Analysts who maintain neutral views, despite higher price targets, indicate that the current share price already reflects a meaningful portion of their expected execution on occupancy improvements and capital deployment.
What's in the News
- Sabra Health Care REIT issued earnings guidance for 2026, outlining expected net income attributable to the company per diluted common share in a range of $0.60 to $0.64. (Key Developments)
- The 2026 guidance is based on an assumption of low single digit Cash NOI growth for the triple net portfolio at the midpoint, with no impact from potential acquisitions or dispositions included. (Key Developments)
Valuation Changes
- Fair Value has risen slightly to $21.92 from $21.85.
- Discount Rate has edged higher to 7.68% from 7.66%.
- Revenue Growth assumption has increased to 12.24% from 9.49%.
- Net Profit Margin assumption has eased to 22.18% from 23.78%.
- Future P/E multiple is essentially unchanged at 33.76x versus 33.77x previously.
Key Takeaways
- Demand for senior housing outpaces supply, boosting occupancy, rents, and long-term cash flow for Sabra as barriers to new development remain high.
- Strategic acquisitions and limited new competition enhance Sabra's pricing power, margin expansion, and diversified growth across attractive healthcare segments.
- Reliance on new operators, aggressive acquisitions, regulatory risks, and limited reinvestment capacity could undermine asset quality, margins, dividend stability, and future growth.
Catalysts
About Sabra Health Care REIT- Sabra Health Care REIT, Inc. as of March 31, 2025 investment portfolio included 364 real estate properties held for investment (consisting of (i) 224 skilled nursing/transitional care facilities, (ii) 39 senior housing communities (senior housing - leased), (iii) 69 senior housing communities operated by third-party property managers pursuant to property management agreements (senior housing - managed), (iv) 17 behavioral health facilities and (v) 15 specialty hospitals and other facilities), 15 investments in loans receivable (consisting of three mortgage loans and 12 other loans), four preferred equity investments and two investments in unconsolidated joint ventures.
- Persistent and accelerating demand for senior housing, assisted living, and memory care driven by the aging U.S. population-specifically the Baby Boomer cohort-continues to outpace new supply due to high barriers to development; this supports higher occupancy, rising rents, and long-term revenue and cash NOI growth across Sabra's property portfolio.
- The limited new development of senior housing driven by elevated construction and financing costs has created a supply-demand imbalance in key markets, giving Sabra pricing power for rent increases and occupancy gains, resulting in expanding margins and boosting net operating income.
- Substantial reinvestment and $500 million in targeted acquisitions, primarily focused on high-quality, newly built senior housing assets attractive to the current age cohort, are expected to fuel external growth and mix shift toward higher-growth, higher-margin properties-directly benefiting earnings, cash flow, and FFO.
- Stable-to-increasing government reimbursement rates in skilled nursing and strong private investment in healthcare infrastructure, combined with Sabra's proactive operator selection and portfolio management, underpin improved rent coverage, reduce income volatility, and underpin future net margin and dividend security.
- Ongoing shift toward value-based and out-of-hospital care settings (assisted living, post-acute, behavioral health) increases long-term need for real estate solutions provided by Sabra, reinforcing multi-year growth in rental income, cash NOI, and AFFO.
Sabra Health Care REIT Future Earnings and Revenue Growth
Assumptions
How have these above catalysts been quantified?
- Analysts are assuming Sabra Health Care REIT's revenue will grow by 12.2% annually over the next 3 years.
- Analysts assume that profit margins will increase from 20.1% today to 22.2% in 3 years time.
- Analysts expect earnings to reach $243.2 million (and earnings per share of $0.83) by about April 2029, up from $155.6 million today.
- In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 33.8x on those 2029 earnings, up from 31.2x today. This future PE is lower than the current PE for the US Health Care REITs industry at 35.4x.
- Analysts expect the number of shares outstanding to grow by 5.97% per year for the next 3 years.
- To value all of this in today's terms, we will use a discount rate of 7.68%, as per the Simply Wall St company report.
Risks
What could happen that would invalidate this narrative?- The portfolio shakeup involving transition of Holiday assets to new operators introduces execution risk; if new operators underperform or the transition is not smooth, occupancy and NOI could suffer, impacting both revenue growth and margin expansion.
- Despite positive near-term demand/supply dynamics, the outlook assumes continued tight supply; if interest rates decline or capital costs ease, new construction could eventually come online and increase competition, leading to lower rental growth and increased vacancy risk, weighing on future revenues.
- The company's pipeline relies heavily on senior housing assets (SHOP) and entails a significant ramp-up in acquisitions; overly aggressive expansion while depending on newer or unproven operators or imperfect asset selection risks diluting asset quality and compressing net margins.
- Regulatory and government reimbursement risk remains; while management downplayed immediate concern, Medicaid and Medicare rates are subject to political and fiscal pressures, and future cuts or slower increases could strain operator coverage ratios and Sabra's rent collection reliability, threatening both revenue and FFO.
- A high payout ratio (dividend at 79% of AFFO) means limited retained cash for reinvestment or deleveraging; if operating or investment performance falters, or if tenant financial health deteriorates, Sabra may be forced to trim its dividend, negatively impacting earnings and share price sentiment.
Valuation
How have all the factors above been brought together to estimate a fair value?
- The analysts have a consensus price target of $21.92 for Sabra Health Care REIT based on their expectations of its future earnings growth, profit margins and other risk factors.
- In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $1.1 billion, earnings will come to $243.2 million, and it would be trading on a PE ratio of 33.8x, assuming you use a discount rate of 7.7%.
- Given the current share price of $19.23, the analyst price target of $21.92 is 12.3% higher.
- We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.
Have other thoughts on Sabra Health Care REIT?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeHow well do narratives help inform your perspective?
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

